

**Title:** Sex differences between females and males in antipsychotic medication efficacy and adverse effects in the treatment of schizophrenia

**Short title:** Sex differences and antipsychotics

**Journal:** CNS Drugs

**Authors:**

**Megan Galbally**<sup>1,2</sup> ORCID [0000-0003-3909-1918](https://orcid.org/0000-0003-3909-1918)

**Karen Wynter**<sup>1,3</sup> ORCID [0000-0003-4620-7691](https://orcid.org/0000-0003-4620-7691)

**Dan Siskind**<sup>4,5</sup> ORCID [0000-0002-2072-9216](https://orcid.org/0000-0002-2072-9216)

**Christoph U. Correll**<sup>6,7,8,9</sup> ORCID [0000-0002-7254-5646](https://orcid.org/0000-0002-7254-5646)

**Korinne Northwood**<sup>4,5</sup> ORCID [0000-0001-6268-547X](https://orcid.org/0000-0001-6268-547X)

**Susanna Every-Palmer**<sup>10</sup> ORCID [0000-0001-6455-9741](https://orcid.org/0000-0001-6455-9741)

**Affiliations:**

1. School of Clinical Sciences, Monash University, Australia
2. Health Futures Institute, Murdoch University, Australia
3. Faculty of Health, Deakin University, Australia
4. Faculty of Medicine, The University of Queensland, Brisbane, Australia
5. Metro South Addiction and Mental Health Hospital and Health Service, Brisbane, Australia
6. Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA
7. Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA
8. Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany
9. German Center for Mental Health (DZPG), partner site Berlin, Germany
10. Department of Psychological Medicine, University of Otago Wellington, New Zealand

**Address Correspondence to:** Professor Megan Galbally, [megan.galbally@monash.edu](mailto:megan.galbally@monash.edu)

Supplementary Table 4: Response as indicated by changes in CGI-S and Calgary Depression rating scale scores (Baseline to End of Phase) by sex, within each treatment group

	Total n	Females			Males			$p^1$	$d$
		Mean	SD	n	Mean	SD	n		
CGIS change score									
Olanzapine	236	-0.37	1.064	68	-0.32	1.057	168	0.747	0.021
Perphenazine	197	-0.31	1.075	48	-0.1	1.149	149	0.084	0.123
Quetiapine	245	-0.02	0.991	55	0.12	1.123	190	0.313	0.064
Risperidone	250	0.12	1.366	68	-0.05	1.001	182	0.244	-0.074
Ziprasidone	122	0.06	1.324	34	0.02	1.144	88	0.995	0.001
Calgary change score									
Olanzapine	238	-0.41	3.732	70	-0.68	3.751	168	0.485	-0.045
Perphenazine	200	-1.29	4.062	49	0.25	4.3941	151	0.025	0.158
Quetiapine	244	-0.3	4.59	57	-0.39	3.667	187	0.808	-0.016
Risperidone	253	0.51	5.221	69	-0.57	4.139	184	0.036	-0.132
Ziprasidone	128	-0.37	3.83	38	0.41	4.869	90	0.709	0.033

CGI-S: Clinical Global Impression Severity scale; SD: standard deviation

<sup>1</sup>  $p$ -values and effect sizes associated with Mann-Whitney U tests